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Abstract
Objective: Translation of women’s mental health research has yet to impact overall prevalence and burden of
Mood Disorders in the United States. The lack of standard measures and methodological coordination across
studies has contributed to the slow impact of research on outcomes. The primary aims of this project were to
demonstrate the process by which multiple investigators, sites, and settings administered a standard women’s
mental health questionnaire within a new Women’s Depression Network. Information on the prevalence of
mental health and service use across sites is provided.
Methods: A standard women’s mental health questionnaire was developed and administered across seven
different women’s health sites in the United States. Validated measures of depression and anxiety were included
(Patient Health Questionnaire Depression Scale [PHQ-9] and Generalized Anxiety Disorder Scale [GAD-7]).
Administration of the questionnaire was embedded into existing clinical or research activities at each site.
Results: Data from 1,316 women were collected from seven sites over 12 months. A total of 14% and 15% of
the women scored at or above the cutoff on the PHQ-9 and GAD-7 respectively. Just over half of the women
screening positive for either depression or anxiety reported current treatment use.
Conclusions: Findings suggest that coordination and administration of a standard women’s mental health
questionnaire is feasible across multiple settings and sites. Results highlight a low percentage of treatment use
across various settings. The infrastructure developed for this study sets the stage for hypothesis-driven studies
that can facilitate coordinated, network-based research that has the potential to accelerate advances in the field.
Keywords: women, screening, depression, anxiety, symptoms
Introduction
Compared with other chronic medical conditions, un-treated depression is associated with the largest negative
impact on health worldwide.1 For women, this finding is
particularly relevant since depression is twice as common
in woman as compared to men, with peak prevalence dur-
ing the childbearing years.2 Approximately 500,000 chil-
dren are born each year in the United States to women with
major depressive disorder (MDD), up to 75% of whom are
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untreated.3,4 Despite the documented harms to women and
children, no effective and sustainable strategies to improve
depression treatment in women’s healthcare settings are in
use throughout the United States, a fact that is striking and
unacceptable.3 It has been argued that a lack of methodo-
logical coordination across similarly focused research studies
has contributed to slow advances in women’s depression re-
search.5 This article presents findings of an effort to coordi-
nate methods across a network of similarly focused women’s
depression researchers.
The limited geographic, economic, and racial/ethnic di-
versity of women participating in perinatal research studies is
also a considerable barrier to progress in improving out-
comes. For example, implementation studies of evidence-
based approaches in diverse sites, settings, and populations
using standard approaches would allow for comparison of
effectiveness across groups. Research results based on a
single region, site, setting, or subgroup of patients may not
generalize to others. The need for studies involving diverse
clinical settings is particularly important. Up to 80% of in-
dividuals with mental health needs, such as depression or
anxiety, present outside of specialty mental health settings. A
recent review by the National Academy of Science pointed to
the clear need for research studies that include assessment
and intervention with diverse populations and within settings
outside of psychiatry, where most women with depression
present for healthcare (e.g., obstetrics and gynecology or
other primary healthcare settings).3
Another fundamental barrier in translating research to
practice is the use of differing methodologies (e.g., measures,
timing of assessments) across individual research studies.
Several national funding and policy-making bodies have
recognized the need for efforts to collect and share standard
mental health data.5,6 Other fields, such as cancer and car-
diovascular disease, have seen drastic improvements in un-
derstanding risk factors and effective treatments largely due
to research networks that employ common data elements.7,8
Use of standard measures across diverse sites and settings has
the promise to accelerate the impact of women’s depression
research. Therefore, larger scale, coordinated research efforts
to address key questions about depression in women must
include geographically and demographically diverse popu-
lations, nonspecialty settings (such as primary care), and
standard measures. There is an urgent need for researchers to
collectively strategize to tackle these problems, not only to
reduce the negative impact of depression on women them-
selves, but also the medical, developmental, and psychiatric
risk to their children.3
In 2007, a collaborative affiliation among academic De-
pression Centers began, known as the National Network of
Depression Centers (NNDC). The NNDC is a network of
clinicians and researchers from 25 academic institutions.
Their goal is to ‘‘use the power of the network to expedite
scientific discovery, to disseminate advancements in patient
care, and to improve quality of life for those with depressive
and bipolar illnesses’’ (www.nndc.org, NNDC website). The
NNDC is comprised of several national Task Groups that
address key areas of Mood Disorders. The Women and Mood
Disorders (W&MD) Task Group is focused on synergistically
advancing the field of women’s depression by capitalizing
upon the power of a collaborative network. In this article, we
describe a multi-institutional collaborative pilot project of
this group aimed to demonstrate the initial feasibility of
collecting standard data regarding women’s health and mood
across a variety of sites and regions affiliated with the NNDC
where women receive healthcare. A single questionnaire was
developed by the W&MD Task Group and administered
across healthcare settings.
This article presents a preliminary demonstration project
that aimed to illustrate whether and how multiple investiga-
tors may administer a standard women’s mental health
questionnaire across multiple sites and types of clinical set-
tings. Specific objectives of the study were as follows: (1) to
identify supports and barriers experienced by participating
investigators, and (2) to explore the usefulness of the data
collected across diverse sites by examining the prevalence of
elevated scores on validated screening tools, the prevalence
of specific symptoms of depression and anxiety, and mental
health service use by the women. This pilot work serves as the
foundation for larger, hypothesis-driven, multisite, collabo-
rative projects to address the methodological limitations
impeding advances in the identification of women with
MDD, the development of effective treatment, and the con-
duct of translational research.
Methods
Procedures
This was a cross-sectional, multisite pilot study. Sites were
selected based on interest of the investigators, and general
feasibility of administering a standard questionnaire within
the time frame of the study either through ongoing clinical or
research activities. Seven clinical sites affiliated with NNDC
Universities participated. Sites included outpatient obstet-
rics/gynecology clinics (n = 4); reproductive psychiatry out-
patient clinics (n = 2) and a neonatal intensive care unit
(n = 1). The a priori target enrollment for each site was a
minimum of 40 women. Eligible participants were English-
speaking women 18 years of age or older receiving healthcare
at one of the participating sites.
All procedures, processes, and identification and resolu-
tion of challenges were decided using a consensus process
during regular teleconference calls with the investigators.
Infrastructure determined to be key to network-based col-
laboration were developed and included templates for In-
stitutional Review Board (IRB) use at each site, a standard
study protocol, a Data Sharing and Use Agreement, and
guidelines for data transmission, cleaning, and analyses.
Each site was required to use the standard screening ques-
tionnaire, but other processes and procedures were custom-
ized to each site to maximize feasibility of questionnaire
administration. Forms were self-completed by the partici-
pants either in article or electronic formats. Original forms
were securely maintained at the study sites and securely
transmitted using deidentified data to a data-coordinating
center at the University of Michigan. The ways in which data
from sites were securely transmitted to the data coordinating
center was allowed to vary. Some sites preferred securely
scanning and sending forms, and others preferred entering
data themselves and sending an electronic database to the
coordinating center.
All procedures were approved by the IRB of each partici-
pating institution. Specific data collection procedures varied
based on IRB requirements and logistical considerations at
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each site. For example, for certain sites an informed consent
was presented to participants and signed before completion of
the questionnaire. In other sites, anonymous completion of the
tool was taken as consent to participate. Either study clinicians
or research assistants (RAs) were present in each of the clinic
sites to administer consent and questionnaires. To maximize
feasibility, each site determined the most practical process for
data collection and transfer at their site. Each participating
investigator was responsible for creating clinician notifica-
tion and risk handling procedures that was customized to their
clinical site (and partners) and their IRB. In all cases, an IRB-
approved suicide risk protocol was in place. All participants
were provided information on depression and resources for
follow-up and treatment as part of participation in the study
and/or as requested. The study was completed between Sep-
tember 2013 and October 2014.
Although this study was not designed to provide infor-
mation on effective implementation outcomes, process in-
formation was gathered from investigators at the study
completion on supports and barriers to participation using
both closed and open-ended questions. Specific process areas
that were assessed included (1) the IRB and administrative
approval process, (2) the recruitment and data collection
process, and (3) utility of the screening form.
Measurement
Members of the W&MD Task Group created the Women’s
Health and Mood Screening Questionnaire (WHMQ) as the
standard measure used in the study. The questionnaire was
developed by consensus among the investigators during the
regular teleconference calls. This questionnaire was designed
to be brief and feasible to administer within the workflow of
diverse clinical contexts and to include validated mental health
measures. It consisted of demographic information (e.g., age,
income, education, relationship status, number of children,
employment status), reproductive status (e.g., menstruating
regularly, pregnant, postmenopausal), validated measures of
current anxiety and depressive symptoms, recent and lifetime
history of mood or anxiety disorders, family history of mental
health problems, and participant mental health treatment use
(e.g., therapy, medication, and other treatments). Although the
focus of our network is depression, there was clear recognition
of the need for expanding the focus to include anxiety given
the comorbidity with depression, the paucity of information on
perinatal anxiety screening.
Depression was measured using the Patient Health Ques-
tionnaire Depression Scale (PHQ-9)9 a nine-item self-report
questionnaire based on the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) criteria for major depres-
sion.9 Scores range from 0 to 27, with higher scores indi-
cating more severe depression. Based on research to date, a
score of 10 or greater is used as a cutoff for clinical depres-
sion.9 Meta-analyses of the PHQ-9 have concluded that its
validity is equal or superior to other established depression
measures. Anxiety was measured with the Generalized An-
xiety Disorder Scale (GAD-7),10 a 7-item scale, with scores
ranging from 0 to 27 and different cut-points to indicate mild
to severe anxiety. Sensitivities for the GAD-7 (using a cut-
point of 10 as indicating anxiety disorder) range from 0.66 to
0.89 and specificities range from 0.80 to 0.82. Higher scores
indicate greater anxiety.
Basic demographic information was collected in addition
to a woman’s reproductive health status and history. Mental
health treatment use was also assessed, specifically coun-
seling, medication, or other treatment for depression, anxiety,
or any other emotional difficulties in the past 2 years and over
the lifetime. Women were asked about their history of MDD
using a one-item, validated question.11 The entire question-
naire took*10 minutes or less to complete.
Data analysis
Given the pilot nature of the study, no a priori sample size
calculations were performed. Our feasibility goal was to re-
cruit a minimum of 40 women within the 1-year recruitment
period at each of the different sites using the same tool. This
number of subjects was large enough to ensure a relatively
small standard error of the proportion of women who would
report health and mood characteristics. Based on the binomial
distribution, the most conservative estimate of the standard
error is when this proportion is 50%. With 500 subjects, this
would yield a standard error not exceeding 2.2%.
Descriptive statistics were used to summarize the propor-
tion of subjects who completed the questionnaire and re-
ported depression, anxiety, and treatment use. A positive
screen for depression or anxiety was operationally defined as
being at or above the cutoff of 10 for either the PHQ-9 or
GAD-7, respectively. Pearson correlation coefficients and
95% confidence intervals were used to assess the relationship
between depression and anxiety.
Results
Investigator feasibility and process
Sample IRB wording that was provided to all site inves-
tigators was identified as extremely useful in developing
applications to the IRB. However, the lengthy IRB approval
process was described as a barrier. Once approvals were
obtained, most of the sites were able to initiate data collection
within a week. Previously established relationships with
clinical staff were seen as a major support in feasibility.
There was variation in agreement rates. Three of the sites
indicated that 76%–100% of women who were approached to
participate agreed to complete the screening form; three sites
reported rates ranging from 50% to 75%, and one site re-
ported 26%–50% agreement. Therefore, most sites found the
data collection to be feasible. Five sites reported that con-
ducting the study within the constraints of other clinical or
research activities was easy or very easy, but two sites found
these constraints to pose challenges. Because the study was
largely unfunded, project cost was identified as the biggest
challenge across sites, and was reported as difficult for four of
the seven sites.
Responses to open-ended questions posed to the investi-
gators indicated a number of supports that were key to suc-
cess of the project at sites: involving students as recruiters
and data collectors, having a ‘‘patient services representa-
tive’’ who approached women and explained the study, in-
corporating the forms into an ongoing study or as part of
standard clinical care, having funding available for RAs, and
getting referrals from research coordinators at the clinical
site. The centralized infrastructure for the overall project was
also identified as very helpful, including troubleshooting by
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the study’s Principal Investigators, the detailed procedural
manual provided to each site, and the flexibility and ease with
which data could be transferred to the central coordinating
center. Barriers included reliance on busy clinic staff to en-
gage women and distribute questionnaires, lack of resources
to pay clinical research coordinators and RAs for recruitment
and data entry, lack of resources to reimburse women for their
time in completing forms, competition with other ongoing
studies for women’s participation, and the inability to upload
data automatically using electronic data capture.
Suggestions to improve relevance for the women were to
(1) add a section to the form where women can identify
specific needs or challenges they are facing and a checklist of
services or referrals they would find useful, (2) assure that
terms used are culturally sensitive and that the form is
available in languages other than English, (3) shorten the
form so that it is more feasible for completion by women in
the clinic waiting room, and (4) integrate the form with a
package that includes a physical health questionnaire to
soften the potentially ‘‘uncomfortable’’ focus on strictly
psychiatric symptoms and history.
Sample characteristics
The total number of questionnaires completed across the
seven sites was 1,316. Table 1 shows the characteristics of
study sites, including institution, type of setting, method of
data collection, and the number of questionnaires collected
at each site. All sites achieved the goal of collecting at least
40 screening tools. Most of the sample was acquired from
obstetric and gynecology clinics. Table 2 displays the char-
acteristics of the total sample including demographics, re-
productive health status, mental health status and severity,
and service use. The average age was 31 years. Approxi-
mately 63% self-reported as White or European American
and 30% as Black or African American. About 20.6% of
women had a high school diploma or less education, 34.5%
reported some college, and 43.7% had a baccalaureate edu-
cation or greater. The average annual household income of
the sample was in the $30,000–$50,000 range. However,
income was widely distributed, with 24.8% reporting
<$15,000 and 6.7% reporting $150,000 or more. Approxi-
mately 68% of the women were married or in a committed
relationship. Almost half of the women worked full time
(48%). The largest proportion of women (65%) were preg-
nant, and only 6% were postmenopausal. The mean score on
the PHQ-9 was 4.3 and the mean on the GAD-7 was 4.4.
Prevalence of depression, anxiety, and mental health
service use
Self-reported risk factors for current depression were
prevalent in this sample. Nearly half of the sample reported
symptoms of depression that would indicate a likely history
of having major depression during their lifetime (45.5%). A
total of 31.2% reported having received a diagnosis of de-
pression and 24.1% had been diagnosed with an anxiety
disorder, and 38.2% indicated that someone in their imme-
diate biological family had been diagnosed with a mental
disorder.
Approximately 14% of the women scored at or above the
cutoff of 10 for depression on the PHQ-9 and 15% for the
cutoff of 10 for anxiety on the GAD-7. Close to 10.4% of
women screened positive for both depression and anxiety
(i.e., scores >10) while another 7.2% screened positive for
one or the other. Roughly 74.7% of women scored negative
for both depression and anxiety. The prevalence of specific
symptoms reported on both the PHQ-9 and GAD-7 is shown
in Table 3. The three most commonly reported depres-
sion symptoms were as follows: tired/little energy, trouble
sleeping, and poor appetite/overeating. In terms of anxiety,
the most commonly reported symptoms in order of frequency
were becoming easily annoyed/irritable, worrying too much,
and feeling nervous or on edge. Scores for depression and
anxiety were significantly correlated (r = 0.80, p< 0.001).
Most women reported no use of counseling or medications
for treatment of mental health problems over the course of
their life (62% and 61%, respectively). However, for those
who had received a diagnosis of depression at some point in
their lives, 88% had received counseling or psychotherapy
and 93% had taken prescription medications for their illness.
Similarly, for women previously diagnosed with an anxiety
disorder, 87% had received counseling or psychotherapy and
92.5% had taken medication. Just over half of the women
with a PHQ-9 score ‡10 on our screening questionnaire re-
ported current use of medications (58%) or counseling (57%)
for depression. Similar rates of medication use (50%) and
counseling (50%) were found among women who scored at
or above a cutoff of 10 on the GAD-7. For women who met
the cutoff for depression and were being seen in psychiatric
Table 1. Characteristics of Sites Participating in Women and Mood Disorder Task Group
Pilot Study (Total n = 1,316)
Institution Setting Data collection process Sample size
University of Michigan Obstetrics Obstetrics staff administered
as part of ongoing registry
66
University of Massachusetts Reproductive Psychiatry Clinic Clinicians administered 159
University of Pennsylvania Reproductive Psychiatry Clinic Clinicians administered 46
Florida State University Obstetrics and Gynecology Clinic Research staff administered 593
Medical University
of South Carolina





Women’s Health Outpatient Clinic Research staff administered 49
University of California,
San Francisco
Neonatal Intensive Care/Obstetrics Research staff administered 59
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settings, 66.7% were receiving therapy/counseling and
44.4% were receiving medications. Nearly 69.2% of women
meeting the cutoff for anxiety in psychiatric settings were in
therapy and 61.5% were taking prescribed medications.
Discussion
Supports and barriers
The establishment and use of a centralized infrastructure to
support site investigators was viewed as critical to the success
of the project, particularly for assisting with IRB protocols
and troubleshooting issues related to data collection and
Table 2. Characteristics of the
Total Sample (n = 1,316)

















$150,000 or more 7 (88)
Relationship status
Never married 25 (325)
Married 52 (680)






HS or GED 19 (250)
Some college 35 (454)
4 year college 25 (325)
Masters degree 13 (174)




Part time or occasional 16 (204)
Full time 48 (628)
Reproductive status
Monthly menstrual period 14 (182)
Pregnant 65 (850)
Postpartum 8 (104)
Irregular menstrual period 4 (49)




Counseling for mental health
Never 62 (811)
Yes, but not past 2 years 14 (182)
Yes, past 2 years but not currently 6 (85)
Yes, currently 16 (216)
Medications for mental health
Never 61 (805)
Yes, but not past 2 years 11 (143)
Yes, past 2 years but not currently 8 (108)






Variable % or mean (SD)









PHQ-9 score 4.3 (5.2)
GAD-7 score 4.4 (5.2)
GAD-7, Generalized Anxiety Disorder Scale; GED, general equiv-
alency diploma; HS, high school; MDD, major depressive disorder;
PHQ-9, Patient Health Questionnaire Depression Scale; SD, standard
deviation.
Table 3. Prevalence of Depression
and Anxiety Symptoms (n = 1,316)
Percent having elevated PHQ-9 scores, GAD-7
scores, and comorbid elevation
PHQ-9 (‡10) 13.8%
GAD-7 (‡10) 15.1%
Comorbid PHQ-9 (‡10) and GAD-7 (‡10) 10.4%
Percent reporting several days or more per week
over past week on PHQ-9 symptoms
Tired/little energy 68% (899)
Trouble sleeping 50% (661)
Poor appetite or overeating 38% (494)
Little interest or pleasure 29% (375)
Down, depressed, hopeless 28% (363)
Feeling bad about self or failure 23% (306)
Trouble concentrating 22% (283)
Moving or speaking slowly 12% (157)
Thoughts of suicide 6% (82)
Percent reporting several days or more per week
over last 2 weeks of GAD-7 symptoms
Becoming easily annoyed or irritable 54% (715)
Worrying too much about different things 48% (627)
Feeling, or on nervous, anxious edge 47% (616)
Trouble relaxing 44% (570)
Not being able to stop or control worrying 37% (488)
Feeling afraid something awful might happen 29% (385)
Being so restless it is hard to sit still 25% (326)
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entry. The primary barrier for some sites was lack of re-
sources to enable adequate staffing for the project. This
finding indicates a need to identify innovative approaches for
integrating the assessment into other ongoing research ini-
tiatives or including the assessment as part of standard clin-
ical care. Other suggestions for improving feasibility include
lobbying third party payers to reimburse clinician time for
screening efforts and shortening the form to reduce the bur-
den for clinicians and patients.
Usefulness of the data acquired
Results indicate that administration of a standard screening
questionnaire was feasible across multiple sites and research
groups. All sites reached the minimal target sample size, and
in some cases greatly exceeded that target. We were able to
screen 1,316 women over a 12-month period using a standard
questionnaire. The study was also successful in using the
questionnaire across the different settings where women
presented for care, including psychiatry, obstetrics/gynecol-
ogy, and neonatal intensive care settings. Collectively, we
recruited a diverse sample in terms of race, ethnicity, socio-
economic status, and healthcare setting. The achievement of
this preliminary coordination and feasibility is promising in
terms of expanding the potential for advancing coordinated
methodology across diverse sites and settings, especially in
light of the lack of study funding.
Rates of depression and anxiety were 13.8% and 15.1%
respectively, based upon established cutoff scores from PHQ-
9 and GAD-7. Our results are in the expected range, com-
parable to the prevalence rates for depression in women
reported in other studies.12–14 Given the diversity in sites and
settings, we were interested in the prevalence of individual
symptoms of depression and anxiety. Surprisingly, ‘‘de-
pressed mood’’ was not a commonly endorsed symptom on
the PHQ-9, but rather somatic symptoms were much more
commonly reported (sleep, appetite, and energy). Less than a
third of women endorsed depressed mood or anhedonia. A
recent study of presenting complaints in obstetric/gynecol-
ogy settings among women with depression similarly found
that only 11% presented with depressed mood, and the ma-
jority presented with a physical complaint.15 However, be-
cause the majority of women in our study were pregnant, we
cannot rule out the possibility that somatic symptoms were
linked to their pregnancy rather than depression. Also of in-
terest was the finding that the most commonly reported
symptom on GAD-7 was ‘‘feeling easily annoyed or irrita-
ble’’ rather than more obvious symptoms of nervousness or
anxiety. These findings have implications for clinicians in
settings that rely on a presenting complaint of depressed
mood or anxious feelings as opposed to validated screening
tools to detect depression or anxiety. Similarly, clinicians and
service providers who ask only about symptoms of depressed
or anxious mood may miss identifying women with different
symptom expressions.
Depression and anxiety were highly correlated with each
other, a finding also shown in previous research.2,16 Their
strong relationship suggests a common internalizing pheno-
type and may explain why essentially the same variables
predicted the likelihood of a woman screening positive for
both depression and anxiety. About half of the sample with
clear risk for depression and anxiety was not receiving any
mental health services, a finding that is in line with estimates
from other studies.17 However, given that a subsample of
women was recruited from psychiatry settings, this rate is
surprisingly low. It is possible that some of the women who
completed the screening tool in psychiatric settings had just
been referred for assessment, with no treatment plan yet
identified. Overall, our findings suggest that women with
mental health problems across different settings are likely
undertreated. The study could not determine whether women
were not being identified within their settings as needing
treatment, that resources were not be available for treatment,
or that they were not choosing treatment as a way to manage
the symptoms. Moreover, depression and anxiety severity
were higher among those individuals indicating that they
were utilizing psychotherapy or pharmacotherapy. It is pos-
sible that they were simply early in their treatment and were
not yet in remission, and that more severe patients were more
likely to receive treatment. However, this finding raises the
concern that even women who are actively utilizing mental
healthcare are not being optimally treated. Further research is
needed to understand these issues and to better address the
mental health needs of women. Because untreated depression
and anxiety have numerous adverse effects,18–20 the lack of
intervention is concerning.
Limitations
A number of limitations should be noted when considering
the findings. The multisite investigators responded to closed
and open-ended questions about the processes used in this
study, and their responses revealed some key facilitators
and barriers to administering the screening tool in these
practices. However, this study was not designed as an im-
plementation science study and did not aim to investigate key
implementation outcomes such as those related to incorpo-
ration of screening procedures into clinical practice versus
another ongoing research study. Such questions will be spe-
cific aims of a follow-up implementation science study. Other
studies that have implemented depression screening in wom-
en’s health sites as part of research have found that flexibility,
clear staff engagement, and briefer screening tools and consents
increased feasibility.21 The sample was strategically recruited
from different types of settings, which introduces sources of
systematic bias in some key outcomes (such as illness severity
and treatment use). In addition, one site had substantially more
women enrolled than other sites, influencing the overall gen-
eralizability across geographic areas. Similarly, variations in
sample size across sites precluded our ability to examine
potential differences within types of settings. These limita-
tions are the precise methodological challenges that must be
addressed in moving forward with larger scale, hypothesis-
driven, and network-based studies that aim to include diverse
samples. Greater statistical power and advanced statistical
methods (such a meta-analytic approaches) may address
these limitations in a way that harnesses the power of col-
laborative research, especially with the use of standard data
collection instruments.
Conclusions
This pilot project effectively demonstrated the feasibility
of administering a standard mental health screening ques-
tionnaire among women across multiple clinical sites and
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settings in the United States. Network-based studies of this
nature require strong collaboration among multiple investi-
gators. The study also provided a preliminary profile of the
prevalence of depression and anxiety among these women
and the potential services they are receiving. The infrastruc-
ture we have developed sets the stage for hypothesis-driven
studies to build knowledge in these areas by capitalizing on
a standardized, network approach. Such an approach can fa-
cilitate scientific development in women’s mental health and
more rapid identification of effective prevention and treat-
ment approaches.
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